Technetium-99m dextran: a promising new protein-losing enteropathy imaging agent

Area of Science:

• Nuclear Medicine
• Gastroenterology
• Radiopharmaceutical Development

Background:

• Protein-losing enteropathy (PLE) is a condition characterized by excessive protein loss into the gastrointestinal tract.
• Accurate diagnosis and localization of PLE are crucial for effective patient management.
• Existing imaging agents may have limitations in sensitivity or specificity.

Purpose of the Study:

• To evaluate technetium-99m dextran (99mTc-Dx) as a novel imaging agent for protein-losing enteropathy (PLE).
• To assess the diagnostic capability of 99mTc-Dx scintigraphy in patients with suspected PLE.

Main Methods:

• Intravenous administration of technetium-99m dextran (99mTc-Dx) in 22 patients with PLE-associated diseases and 12 healthy controls.
• Whole-body scintigraphy was performed to detect radiotracer distribution and accumulation.
• Analysis of tracer localization to identify the nature and extent of intestinal involvement.

Main Results:

• All 22 patients with PLE demonstrated significant intestinal accumulation of 99mTc-Dx within 3-4 hours post-injection.
• The imaging agent helped differentiate focal, regional, or generalized enteropathy and identified small or large intestine involvement in most cases.
• Four healthy subjects showed minimal late abdominal accumulation, potentially due to physiological factors or undetected conditions.

Conclusions:

• Technetium-99m dextran (99mTc-Dx) exhibits high sensitivity for detecting protein-losing enteropathy (PLE).
• The agent's rapid blood clearance contributes to its effectiveness in imaging PLE.
• 99mTc-Dx offers potential advantages over other agents like 99mTc-labelled human serum albumin for PLE imaging.